Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension

Biochemical and Biophysical Research Communications

Volumn 451, Issue 1, 2014, Pages 8-14

  Shao, Dongmin ^a   Perros, Frédéric ^b   Caramori, Gaetano ^c   Meng, Chao ^a,e   Dormuller, Peter ^b   Chou, Pai Chien ^d   Church, Colin ^f   Papi, Alberto ^c   Casolari, Paolo ^c   Welsh, David ^f   Peacock, Andrew ^f   Humbert, Marc ^b   Adcock, Ian M ^d   Wort, Stephen J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF FERRARA   (Italy)

^d National Heart and Lung Institute   (United Kingdom)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Human endothelial cells; IL 33; Nuclear repressor; Pulmonary hypertension; Soluble ST2

Indexed keywords

FRACTALKINE; HISTONE METHYLTRANSFERASE; HOMEODOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; RANTES; SMALL INTERFERING RNA; SUPPRESSOR OF TUMOUROGENICITY 2 RECEPTOR; UNCLASSIFIED DRUG; AUTACOID; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ARTICLE; BLOOD LEVEL; BLOOD VESSEL; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN PULMONARY ARTERIAL ENDOTHELIAL CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LUNG PARENCHYMA; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; PULMONARY HYPERTENSION; TIGHT JUNCTION; UPREGULATION; BINDING SITE; BLOOD; CASE CONTROL STUDY; CELL CULTURE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

BASE SEQUENCE; BINDING SITES; CASE-CONTROL STUDIES; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FAMILIAL PRIMARY PULMONARY HYPERTENSION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKINS; LUNG; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84906240585     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.06.111     Document Type: Article

References (52)

1. D. Shao, J.E. Park, and S.J. Wort The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension Pharmacol. Res. 63 2011 504 511
2. P. Dorfmuller, F. Perros, K. Balabanian, and M. Humbert Inflammation in pulmonary arterial hypertension Eur. Respir. J. 22 2003 358 363
3. M. Humbert, G. Monti, and F. Brenot et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension Am. J. Respir. Crit. Care Med. 151 1995 1628 1631
4. F. Perros, P. Dorfmuller, and R. Souza et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension Eur. Respir. J. 29 2007 937 943
5. P. Dorfmuller, V. Zarka, and I. Durand-Gasselin et al. Chemokine RANTES in severe pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 165 2002 534 539
6. O. Sanchez, E. Marcos, and F. Perros et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 176 2007 1041 1047
7. L.C. Price, G. Caramori, and F. Perros et al. Nuclear factor kappa-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension PLoS ONE 8 2013 e75415
8. G. Haraldsen, J. Balogh, J. Pollheimer, J. Sponheim, and A.M. Kuchler Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol. 30 2009 227 233
9. M. Lamkanfi, and V.M. Dixit IL-33 raises alarm Immunity 31 2009 5 7
10. D.E. Smith IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma Clin. Exp. Allergy 40 2010 200 208
11. F.Y. Liew, N.I. Pitman, and I.B. McInnes Disease-associated functions of IL-33: the new kid in the IL-1 family Nat. Rev. Immunol. 10 2010 103 110
12. C. Cayrol, and J.P. Girard The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1 Proc. Natl. Acad. Sci. U.S.A. 106 2009 9021 9026
13. S. Tominaga A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor FEBS Lett. 258 1989 301 304
14. J. Schmitz, A. Owyang, and E. Oldham et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines Immunity 23 2005 479 490
15. K. Yoshida, T. Arai, and T. Yokota et al. Studies on natural ST2 gene products in the human leukemic cell line UT-7 using monoclonal antihuman ST2 antibodies Hybridoma 14 1995 419 427
16. E.S. Baekkevold, M. Roussigne, and T. Yamanaka et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules Am. J. Pathol. 163 2003 69 79
17. M.M. Bunting, A.M. Shadie, and R.P. Flesher et al. Interleukin-33 drives activation of alveolar macrophages and airway inflammation in a mouse model of acute exacerbation of chronic asthma Biomed. Res. Int. 2013 2013 250938
18. K. Oboki, S. Nakae, K. Matsumoto, and H. Saito IL-33 and airway inflammation Allergy Asthma Immunol. Res. 3 2011 81 88
19. D.E. Byers, J. Alexander-Brett, and A.C. Patel et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease J. Clin. Invest. 123 2013 3967 3982
20. A. Di Stefano, G. Caramori, and A. Barczyk et al. Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD Thorax 69 2014 516 524
21. S. Sanada, D. Hakuno, and L.J. Higgins et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system J. Clin. Invest. 117 2007 1538 1549
22. K. Seki, S. Sanada, and A.Y. Kudinova et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling Circ. Heart Fail. 2 2009 684 691
23. A.M. Miller, D. Xu, and D.L. Asquith et al. IL-33 reduces the development of atherosclerosis J. Exp. Med. 205 2008 339 346
24. A. Bhardwaj, and J.L. Januzzi Jr. ST2: a novel biomarker for heart failure Expert Rev. Mol. Diagn. 10 2010 459 464
25. A. Martinez-Rumayor, C.A. Camargo, and S.M. Green et al. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease Am. J. Clin. Pathol. 130 2008 578 584
26. G. Carlomagno, G. Messalli, and R.M. Melillo et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension Int. J. Cardiol. 168 2013 1545 1547
27. J.E. Park, D. Shao, and P.D. Upton et al. BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production PLoS ONE 7 2012 e30075
28. K. Ito, S. Yamamura, and S. Essilfie-Quaye et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression J. Exp. Med. 203 2006 7 13
29. A.M. Kuchler, J. Pollheimer, and J. Balogh et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation Am. J. Pathol. 173 2008 1229 1242
30. V. Carriere, L. Roussel, and N. Ortega et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo Proc. Natl. Acad. Sci. U.S.A. 104 2007 282 287
31. S.A. Antoniu Targeting PDGF pathway in pulmonary arterial hypertension Expert Opin. Ther. Targets 16 2012 1055 1063
32. G. Hansmann, V.A. de Jesus Perez, and T.P. Alastalo et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension J. Clin. Invest. 118 2008 1846 1857
33. H.J. Mortimer, A.J. Peacock, A. Kirk, and D.J. Welsh P38 MAP kinase: essential role in hypoxia-mediated human pulmonary artery fibroblast proliferation Pulm. Pharmacol. Ther. 20 2007 718 725
34. R.V. Shah, and J.L. Januzzi Jr. ST2: a novel remodeling biomarker in acute and chronic heart failure Curr. Heart Fail. Rep. 7 2010 9 14
35. J. Gillibert-Duplantier, B. Duthey, and V. Sisirak et al. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis Oncogene 31 2012 3516 3524
36. B.W. Fouty, B. Grimison, and K.A. Fagan et al. P27(Kip1) is important in modulating pulmonary artery smooth muscle cell proliferation Am. J. Respir. Cell Mol. Biol. 25 2001 652 658
37. Y. Liu, Y.J. Suzuki, R.M. Day, and B.L. Fanburg Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin Circ. Res. 95 2004 579 586
38. Y.J. Suzuki, R.M. Day, and C.C. Tan et al. Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells J. Biol. Chem. 278 2003 17525 17531
39. H.A. Ghofrani, N.W. Morrell, and M.M. Hoeper et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy Am. J. Respir. Crit. Care Med. 182 2010 1171 1177
40. B.K. Dahal, T. Cornitescu, and A. Tretyn et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension Am. J. Respir. Crit. Care Med. 181 2010 158 167
41. S. Ali, A. Mohs, and M. Thomas et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription J. Immunol. 187 2011 1609 1616
42. Y.S. Choi, J.A. Park, and J. Kim et al. Nuclear IL-33 is a transcriptional regulator of NF-kappaB p65 and induces endothelial cell activation Biochem. Biophys. Res. Commun. 421 2012 305 311
43. Y. Baba, K. Maeda, and T. Yashiro et al. GATA2 is a critical transactivator for the human IL1RL1/ST2 promoter in mast cells/basophils: opposing roles for GATA2 and GATA1 in human IL1RL1/ST2 gene expression J. Biol. Chem. 287 2012 32689 32696
44. B.P. Lipsky, D.Y. Toy, D.A. Swart, M.D. Smithgall, and D. Smith Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation Eur. J. Immunol. 42 2012 1863 1869
45. S. Aoki, M. Hayakawa, and H. Ozaki et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells Mol. Cell. Biochem. 335 2010 75 81
46. A. Rascle, T. Neumann, and A.S. Raschta et al. The LIM-homeodomain transcription factor LMX1B regulates expression of NF-kappa B target genes Exp. Cell Res. 315 2009 76 96
47. J.E. Irazoqui, A. Ng, R.J. Xavier, and F.M. Ausubel Role for beta-catenin and HOX transcription factors in Caenorhabditis elegans and mammalian host epithelial-pathogen interactions Proc. Natl. Acad. Sci. U.S.A. 105 2008 17469 17474
48. H. El Chami, and P.M. Hassoun Immune and inflammatory mechanisms in pulmonary arterial hypertension Prog. Cardiovasc. Dis. 55 2012 218 228
49. K. Oboki, T. Ohno, and N. Kajiwara et al. IL-33 is a crucial amplifier of innate rather than acquired immunity Proc. Natl. Acad. Sci. U.S.A. 107 2010 18581 18586
50. R. Kakkar, H. Hei, and S. Dobner et al. Interleukin 33 as a mechanically responsive cytokine secreted by living cells J. Biol. Chem. 287 2012 6941 6948
51. J. Bessa, C.A. Meyer, and M.C. de Vera Mudry et al. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation J. Autoimmun. 2014 10.1016/j.jaut.2014.02.012 [Epub ahead of print]
52. S.L. Archer, E.K. Weir, and M.R. Wilkins Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies Circulation 121 2010 2045 2066